Journal of Clinical and Translational Hepatology最新文献_第9页

Update on the STING Signaling Pathway in Developing Nonalcoholic Fatty Liver Disease 非酒精性脂肪肝的STING信号通路研究进展

3区医学

Journal of Clinical and Translational Hepatology Pub Date : 2023-09-28 DOI: 10.14218/jcth.2023.00197

Wei Liu, Zhili Zhang Chen, Chenhui Yang, Yaofu Fan, Liang Qiao, Shaofeng Xie, Lin Cao

引用次数: 0

Associations Between Active, Passive Smoking and the Risk of Nonalcoholic Fatty Liver Disease 主动、被动吸烟与非酒精性脂肪肝风险之间的关系

3区医学

Journal of Clinical and Translational Hepatology Pub Date : 2023-09-19 DOI: 10.14218/jcth.2023.00165

Xinyuan Ge, Jing Lu, Chengxiao Yu, Wen Guo, Ting Tian, Xin Xu, Yuqing Ding, Jiaxin Gao, Wei Zhao, Xiaohua Zhou, Qingqing Diao, Hongxia Ma, Qun Zhang, Ci Song, Hongbing Shen

引用次数: 0

Novel Approaches to Inhibition of HBsAg Expression from cccDNA and Chromosomal Integrants: A Review cccDNA和染色体整合体抑制HBsAg表达的新方法综述

3区医学

Journal of Clinical and Translational Hepatology Pub Date : 2023-09-19 DOI: 10.14218/jcth.2023.00067

Ahmed H. Abdelwahed, Brent D. Heineman, George Y. Wu

{"title":"Novel Approaches to Inhibition of HBsAg Expression from cccDNA and Chromosomal Integrants: A Review","authors":"Ahmed H. Abdelwahed, Brent D. Heineman, George Y. Wu","doi":"10.14218/jcth.2023.00067","DOIUrl":"https://doi.org/10.14218/jcth.2023.00067","url":null,"abstract":"Hepatitis B virus (HBV) is a widely prevalent liver infection that can cause acute or chronic hepatitis. Although current treatment modalities are highly effective in the suppression of viral levels, they cannot eliminate the virus or achieve definitive cure. This is a consequence of the complex nature of HBV-host interactions. Major challenges to achieving sustained viral suppression include the presence of a high viral burden from the HBV DNA and hepatitis B surface antigen (HBsAg), the presence of reservoirs for HBV replication and antigen production, and the HBV-impaired innate and adaptive immune response of the host. Those therapeutic methods include cell entry inhibitors, HBsAg inhibitors, gene editing approaches, immune-targeting therapies and direct inhibitors of covalently closed circular DNA (cccDNA). Novel approaches that target these key mechanisms are now being studied in preclinical and clinical phases. In this review article, we provide a comprehensive review on mechanisms by which HBV escapes elimination from current treatments, and highlight new agents to achieve a definitive HBV cure.","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135015438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link 非酒精性脂肪性肝病和肠道微生物群:不可分割的联系

3区医学

Journal of Clinical and Translational Hepatology Pub Date : 2023-09-15 DOI: 10.14218/jcth.2023.00069

Maria Effenberger, Christoph Grander, Felix Grabherr, Herbert Tilg

{"title":"Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link","authors":"Maria Effenberger, Christoph Grander, Felix Grabherr, Herbert Tilg","doi":"10.14218/jcth.2023.00069","DOIUrl":"https://doi.org/10.14218/jcth.2023.00069","url":null,"abstract":"Nonalcoholic fatty liver disease (NAFLD) particularly affects patients with type 2 diabetes and obesity. The incidence of NAFLD has increased significantly over the last decades and is now pandemically across the globe. It is a complex systemic disease comprising hepatic lipid accumulation, inflammation, lipotoxicity, gut dysbiosis, and insulin resistance as main features and with the potential to progress to cirrhosis and hepatocellular carcinoma (HCC). In numerous animal and human studies the gut microbiota plays a key role in the pathogenesis of NAFLD, NAFLD-cirrhosis and NAFLD-associated HCC. Lipotoxicity is the driver of inflammation, insulin resistance, and liver injury. Likewise, western diet, obesity, and metabolic disorders may alter the gut microbiota, which activates innate and adaptive immune responses and fuels hereby hepatic and systemic inflammation. Indigestible carbohydrates are fermented by the gut microbiota to produce important metabolites, such as short-chain fatty acids and succinate. Numerous animal and human studies suggested a pivotal role of these metabolites in the progression of NAFLD and its comorbidities. Though, modification of the gut microbiota and/or the metabolites could even be beneficial in patients with NAFLD, NAFLD-cirrhosis, and NAFLD-associated HCC. In this review we collect the evidence that exogenous and endogenous hits drive liver injury in NAFLD and propel liver fibrosis and the progressing to advanced disease stages. NAFLD can be seen as the product of a complex interplay between gut microbiota, the immune response and metabolism. Thus, the challenge will be to understand its pathogenesis and to develop new therapeutic strategies.","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135353928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive Bile Acid Profiling of ABCB4-mutated Patients and the Prognostic Role of Taurine-conjugated 3α,6α,7α,12α-Tetrahydroxylated Bile Acid in Cholestasis abcb4突变患者的综合胆汁酸谱及牛磺酸偶联的3α，6α，7α，12α-四羟化胆汁酸在胆汁淤积症中的预后作用

3区医学

Journal of Clinical and Translational Hepatology Pub Date : 2023-09-15 DOI: 10.14218/jcth.2023.00095

Teng Liu, Ren-Xue Wang, Jun Han, Zhong-Die Li, Jonathan A. Sheps, Li-Juan Zheng, Xiao-Xiao Xu, Victor Ling, Jian-She Wang

引用次数: 0

Synchronous Double Primary Combined Hepatocellular-cholangiocarcinoma and Cholangiolocarcinoma in a Cirrhotic Liver. 肝硬化肝细胞胆管癌和胆管癌的同步双原发合并。

IF 3.6 3区医学

Journal of Clinical and Translational Hepatology Pub Date : 2023-08-28 DOI: 10.14218/JCTH.2022.00382

Masahiro Sakata, Koji Kitada, Rika Omote, Hiroshi Sonobe, Masashi Utsumi, Naoyuki Tokunaga, Takashi Fushimi, Ryota Nagao, Tatsuro Sakata, Toshihiko Kaneyoshi, Tatsuya Toyokawa, Masaru Inagaki

{"title":"Synchronous Double Primary Combined Hepatocellular-cholangiocarcinoma and Cholangiolocarcinoma in a Cirrhotic Liver.","authors":"Masahiro Sakata, Koji Kitada, Rika Omote, Hiroshi Sonobe, Masashi Utsumi, Naoyuki Tokunaga, Takashi Fushimi, Ryota Nagao, Tatsuro Sakata, Toshihiko Kaneyoshi, Tatsuya Toyokawa, Masaru Inagaki","doi":"10.14218/JCTH.2022.00382","DOIUrl":"https://doi.org/10.14218/JCTH.2022.00382","url":null,"abstract":"Both combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and cholangiolocarcinoma are rare primary liver cancers. cHCC-CCA is believed to originate from transformed hepatocellular carcinoma or liver stem/progenitor cells. Cholangiolocarcinoma is characterized by ductular reaction-like anastomosing cords and glands resembling cholangioles or canals containing hepatocellular carcinoma components and adenocarcinoma cells. According to the 2019 revision of the World Health Organization criteria, a subtype with stem cell features as a subclassification of cHCC-CCA was abolished for lack of conclusive evidence of the stem cell origin theory. That led to the classification of cholangiolocarcinoma with hepatocytic differentiation as cHCC-CCA. Consequently, cholangiolocarcinoma without hepatocytic differentiation is classified as a subtype of small-duct cholangiocarcinoma and is assumed to originate from the bile duct. Herein, we report the first case of double primary cHCC-CCA and cholangiolocarcinoma without hepatocytic differentiation in different hepatic segments of a cirrhotic liver. We believe this case supports the validity of the new World Health Organization criteria because the pathological finding of cHCC-CCA in this case shows the transformation of hepatocellular carcinoma to cholangiocarcinoma. Furthermore, this case may demonstrate that immature ductular cell stemness and mature hepatocyte cell stemness in hepatocarcinogenesis can coexist in the same environment. The results provide valuable insights into the mechanisms of growth, differentiation, and regulation of liver cancers.","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"11 4","pages":"991-997"},"PeriodicalIF":3.6,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/32/JCTH-11-991.PMC10318272.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10162109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic Efficacy and Possible Underlying Mechanisms of Noninvasive Clinical Markers in Hepatocellular Carcinoma. 非侵入性临床标志物在肝细胞癌中的诊断效果及可能的潜在机制。

IF 3.6 3区医学

Journal of Clinical and Translational Hepatology Pub Date : 2023-08-28 DOI: 10.14218/JCTH.2022.00285

Chao-Xu Fu, Jun Li, Zheng-Da Chen, Yan-Ping Cao, Hong-Ling Zhang, Hong-Ting Sui, Bao-Cheng Shan, Lei Xu, Yang Zhou, Min Zhou, En-Yue Yang, Hong-Xin Piao

{"title":"Diagnostic Efficacy and Possible Underlying Mechanisms of Noninvasive Clinical Markers in Hepatocellular Carcinoma.","authors":"Chao-Xu Fu, Jun Li, Zheng-Da Chen, Yan-Ping Cao, Hong-Ling Zhang, Hong-Ting Sui, Bao-Cheng Shan, Lei Xu, Yang Zhou, Min Zhou, En-Yue Yang, Hong-Xin Piao","doi":"10.14218/JCTH.2022.00285","DOIUrl":"https://doi.org/10.14218/JCTH.2022.00285","url":null,"abstract":"Background and aims: In this study, we aimed to evaluate the diagnostic values of alpha-fetoprotein (AFP), soluble AXL (sAXL), des-γ-carboxy prothrombin (DCP), the aspartate aminotransferase-to-platelet ratio index (APRI), and the gamma-glutamyl transpeptidase-to-platelet ratio (GPR) in hepatocellular carcinoma (HCC) and the possible underlying mechanisms of the correlations between them.Methods: We collected serum samples from 190, 128, and 75 patients with HCC, cirrhosis, and chronic viral hepatitis, and from 82 healthy subjects. Serum levels of AFP, sAXL, and DCP were determined, and APRI and GPR values were calculated. Receiver operating characteristic (ROC) curves were used to analyze the diagnostic value of single and combined biomarkers.Results: We detected significant differences between the HCC group and other groups regarding serum AFP, sAXL, DCP, and APRI levels. GPR significantly differed between the HCC group and other groups, except for the liver cirrhosis group. AFP, sAXL, DCP, APRI, and GPR had positive correlations with each other, and AFP showed a higher area under the curve (AUC) and Youden index values, while APRI and DCP showed the highest sensitivity and specificity. Also, when AFP was combined with sAXL, DCP, APRI, and GRP, the highest AUC (0.911) and a higher net reclassification improvement value were obtained compared with those obtained for the individual biomarkers.Conclusions: AFP, sAXL, DCP, APRI, and GPR are independent risk factors for HCC, and the diagnostic performance of AFP combined with sAXL, DCP, APRI, and GPR for HCC diagnosis was superior to that of the individual biomarkers.","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"11 4","pages":"889-898"},"PeriodicalIF":3.6,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/5f/JCTH-11-889.PMC10318273.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10162114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Secondary Iron Overload and the Liver: A Comprehensive Review. 继发性铁超载与肝脏:综合综述。

IF 3.6 3区医学

Journal of Clinical and Translational Hepatology Pub Date : 2023-08-28 DOI: 10.14218/JCTH.2022.00420

Kanokwan Pinyopornpanish, Adisak Tantiworawit, Apinya Leerapun, Atiwat Soontornpun, Satawat Thongsawat

{"title":"Secondary Iron Overload and the Liver: A Comprehensive Review.","authors":"Kanokwan Pinyopornpanish, Adisak Tantiworawit, Apinya Leerapun, Atiwat Soontornpun, Satawat Thongsawat","doi":"10.14218/JCTH.2022.00420","DOIUrl":"https://doi.org/10.14218/JCTH.2022.00420","url":null,"abstract":"Iron overload is a condition involving excessive iron deposit in various organs, the liver being the main target organ for iron deposition and overload which are associated with significant liver morbidity and mortality. Iron overload can be categorized into primary and secondary causes. Primary iron overload, so-called hereditary hemochromatosis, is a well-recognized disease with available standard treatment recommendations. However, secondary iron overload is a more diverse disease with many unclear areas to be explored. Secondary iron overload is more prevalent than primary iron overload and occurs as a consequence of various causes which differ significantly across geographic regions. The main causes of secondary iron overload are iron-loading anemias, and chronic liver disease. The liver-related outcomes, patient outcomes, and treatment recommendations in these patients differ depending on the cause of iron overload. This review summarizes the causes, pathophysiology, liver-related outcomes, disease outcomes, and treatments of secondary iron overload.","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"11 4","pages":"932-941"},"PeriodicalIF":3.6,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/fd/JCTH-11-932.PMC10318281.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9807303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Primary Hepatic Extra-gastrointestinal Stromal Tumors: Molecular Pathogenesis, Immunohistopathology, and Treatment. 原发性肝脏胃肠道外间质瘤:分子发病机制、免疫组织病理学和治疗。

IF 3.6 3区医学

Journal of Clinical and Translational Hepatology Pub Date : 2023-08-28 DOI: 10.14218/JCTH.2022.00173

Erica C Becker, Gonca Ozcan, George Y Wu

{"title":"Primary Hepatic Extra-gastrointestinal Stromal Tumors: Molecular Pathogenesis, Immunohistopathology, and Treatment.","authors":"Erica C Becker, Gonca Ozcan, George Y Wu","doi":"10.14218/JCTH.2022.00173","DOIUrl":"https://doi.org/10.14218/JCTH.2022.00173","url":null,"abstract":"Gastrointestinal stromal tumors are the most common mesenchymal tumors of the gastrointestinal tract. They originate from the interstitial cells of Cajal and are usually found in extrahepatic gastrointestinal sites. However, a small subset are derived from the liver and are known as primary hepatic gastrointestinal stromal tumors (PHGIST). They have a poor prognosis and are historically difficult to diagnose. Our objective was to review and update the latest evidence-based knowledge concerning PHGIST, with a focus on epidemiology, etiology, pathophysiology, clinical presentation, histopathology, and treatment. These tumors are usually found incidentally, occur sporadically, and are associated with mutations of KIT and PDGFRA genes. PHGIST is a diagnosis of exclusion, as it has the same molecular, immunochemistry and histological appearance as gastrointestinal stromal tumors (GIST). Thus, imaging, such as positron emission tomography-computed tomography (PET-CT) must be used to rule out metastatic GIST before a diagnosis can be made. However, with mutation analysis and pharmacological advances, tyrosine kinase inhibitors are typically pursued with or without surgical intervention. Other potential treatments include transcatheter arterial chemoembolization and tumor ablation. However, these are typically considered palliative options. As there are only a limited number of publications regarding PHGIST, data concerning morbidity and mortality are not yet available. Immunohistopathology can help develop screening guidelines and evaluating resistance to treatment.","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"11 4","pages":"942-948"},"PeriodicalIF":3.6,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/05/JCTH-11-942.PMC10318283.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9859826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liver Stiffness Measurement can Predict Liver Inflammation in Chronic Hepatitis B Patients with Normal Alanine Transaminase. 肝硬度测定可预测丙氨酸转氨酶正常的慢性乙型肝炎患者的肝脏炎症。

IF 3.6 3区医学

Journal of Clinical and Translational Hepatology Pub Date : 2023-08-28 DOI: 10.14218/JCTH.2022.00329

Ling-Ling Huang, Xue-Ping Yu, Qing-Fa Ruan, Yan-Xue Lin, Huan Li, Wen Jin, Rui-Feng Liu, Yan-Lan Liang, Yu-Rui Liu, Yue-Yong Zhu, Jia-Ji Jiang, Ri-Cheng Mao, Da-Wu Zeng

{"title":"Liver Stiffness Measurement can Predict Liver Inflammation in Chronic Hepatitis B Patients with Normal Alanine Transaminase.","authors":"Ling-Ling Huang, Xue-Ping Yu, Qing-Fa Ruan, Yan-Xue Lin, Huan Li, Wen Jin, Rui-Feng Liu, Yan-Lan Liang, Yu-Rui Liu, Yue-Yong Zhu, Jia-Ji Jiang, Ri-Cheng Mao, Da-Wu Zeng","doi":"10.14218/JCTH.2022.00329","DOIUrl":"https://doi.org/10.14218/JCTH.2022.00329","url":null,"abstract":"Background and Aims To determine whether liver stiffness measurement (LSM) indicates liver inflammation in chronic hepatitis B (CHB) with different upper limits of normal (ULNs) for alanine aminotransferase (ALT). Methods We grouped 439 CHB patients using different ULNs for ALT: cohort I, ≤40 U/L (439 subjects); cohort II, ≤35/25 U/L (males/females; 330 subjects); and cohort III, ≤30/19 U/L (males/females; 231 subjects). Furthermore, 84 and 96 CHB patients with normal ALT (≤40 U/L) formed the external and prospective validation groups, respectively. We evaluated the correlation between LSM and biopsy-confirmed liver inflammation, and determined diagnostic accuracy using area under the curve (AUC). A noninvasive LSM-based model was developed using multivariate logistic regression. Results Fibrosis-adjusted LSM values significantly increased with increasing inflammation. The AUCs of LSM in cohorts I, II, and III were 0.799, 0.796, and 0.814, respectively, for significant inflammation (A≥2) and 0.779, 0.767, and 0.770, respectively, for severe inflammation (A=3). Cutoff LSM values in all cohorts for A≥2 and A=3 were 6.3 and 7.5 kPa, respectively. Internal, external, and prospective validations showed high diagnostic accuracy of LSM for A≥2 and A=3, and no significant differences in AUCs among the four groups. LSM and globulin independently predicted A≥2. The AUC of an LSM-globulin model for A≥2 exceeded those of globulin, ALT, and AST, but was similar to that of LSM. Conclusions LSM predicted liver inflammation and guided the indication of antiviral therapy for CHB in patients with normal ALT.","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"11 4","pages":"817-826"},"PeriodicalIF":3.6,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f0/61/JCTH-11-817.PMC10318296.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10162108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0